GW Pharma initiates Ph IIa study of cannabinoid in diabetes

1 October 2010

UK-based GW Pharmaceuticals (GWP: AIM) has commenced the first of a program of Phase IIa exploratory clinical trials exploring its cannabinoids as potential treatments in the field of type 2 diabetes and metabolic syndrome. This study program follows promising preclinical research results and comprises at least three small-scale clinical trials evaluating various metabolic parameters.

GW this year announced the UK launch of its cannabis-based Sativex, a prescription-only oromucosal spray for the treatment of spasticity due to multiple sclerosis (The Pharma Letter June 21).

The first Phase IIa study to commence is a multicenter, randomized, double blind, placebo controlled, parallel group pilot study in the treatment of dyslipidemia in patients with type 2 diabetes. A total of 50 patients will be divided into five treatment groups comprising four different cannabinoid formulations and placebo. Following a 2-5 week baseline period, the treatment duration will be 13 weeks.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK